Join us for this open forum hybrid discussion on diagnosis and management of hypertrophic cardiomyopathies in both perioperative and long-term settings #MedEd #FOMed with Antonis Pantazis Thor Edvardsen Eugene Braunwald iacopo olivotto #echofirst

A great day for HCM and med Rx. Aficamten benefits seen in SEQUOIA trial across all primary & secondary endpoints - gradients, BNP, KCCQ ALL improved - NYHA improved by 1 class in half - Modest pVO2 inc by 1.8 - LVEF reductions were not significant. Another CMI for pts!

Very important session on pregnancy in cardiomyopathies with fantastic experts @MTome for HCM, @Karen.Sliwa1 for ACM, kalliopi keramida (Cardio-Oncology Athens) for postcancer and dr Upasana Tayal for peripartum.

IMPROVE-HCM: Targeting myocardial energetics with a novel mitotrope drug, #ninerafaxstat, was safe and improved exercise capacity and symptoms in nonobstructive #HCM. bit.ly/3wL3jok #JACC #cvHCM Betty Raman Daniele Massera SharonCresciMD Matthew W Martinez Martin Maron, MD

🫀 #AtrialFibrillation and LA myopathy in #HypertrophicCardiomyopathy: - Highly prevalent - Close pathophysiology - Are they both associated with increased stroke risk? Read more in #CJC 👉 onlinecjc.ca/article/S0828-… #CardioEd #CardioTwitter #HCM #Mavacamten

🏅 Top Italian Women Scientists 2024: premiate nove ricercatrici dell’Università di Firenze. Ben cinque sono professioniste di Careggi.

Original Article: Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy (SEQUOIA-HCM trial) nej.md/3wmDzyl Editorial: Sixty Years of Hemodynamic Pharmacology in Obstructive Hypertrophic Cardiomyopathy nej.md/4bnvcBe #Cardiology

#HCM hypertrophic #cardiomyopathy & #SICD #ICD what's the outcome? 💚S-ICDs often implanted in pts w low-intermediate ESC SCD risk 💚S-ICD effective in the detection of sub-clinical AF Discover more here👇 DOI: 10.1016/j.ijcard.2024.132202 Istituto Auxologico Italiano Lia Crotti

Congrats to Tatiana Saul, Quan Bui Alessia Argirio and colleagues for getting our paper on Thin Filament Cardiomyopathies accross the finish line! #thepeoplesfilament UC San Diego Cardiology Quan Bui Alessia Argiró iacopo olivotto onlinelibrary.wiley.com/doi/10.1002/eh…

A novel tool for arrhythmic risk stratification in desmoplakin gene variant carriers. Discover more in #EHJ 👉 bit.ly/3YjZBNI Rocco Montone EHJ Editor-in-Chief

Scientists need more time to think 🧠 nature

I have seen or come across at least 5 patients without LVOTO at baseline who were receiving mavacamten commercially. Typically patients have pap-septal contact in mid LV or just have some intraventricular gradient at end systole. Reminder that only LVOTO from SAM-septal contact

& for modern medical tx for obstructive #HCM fr iacopo olivotto #ESCCongress European Society of Cardiology Cardiomyopathy UK

The Pro&Con discussion continues as iacopo olivotto highlights the updated position of #CMI in the recent American College of Cardiology guidelines and the need for patient-centered decision Silvia Castelletti Sara Moscatelli Kristina Haugaa

Great debate: device-detected subclinical atrial fibrillation should be treated like clinical atrial fibrillation European Society of Cardiology Journals European Society of Cardiology academic.oup.com/eurheartj/arti…

Future of HCM is bright and promising!!!😉 Sección Cardiopatías Familiares y Genética CV SEC Área Sanitaria da Coruña e Cee Jesus Peteiro

Great session about #HCM. Congrats Roberto Barriales-Villa iacopo olivotto and P. Elliott #ESC2024

#Aficamten 1/6 presentation. Follow along Here are the results of the #SEQUOIA #HCM #whyCMR substudy (aficamten vs placebo on oHCM) which is also simultaneously published in JACC Journals #CardioTwitter

Left #London with the heart full of joy for have met old and new friends, have joined my first #EHJ family dinner and have discussed important future projects on #echofirst #MMI #cardiomyopathies! Maurizio Pieroni iacopo olivotto Nina Ajmone Marsan C Bucciarelli-Ducci #ESCCongress2024